DE60228056D1 - Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1 - Google Patents

Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1

Info

Publication number
DE60228056D1
DE60228056D1 DE60228056T DE60228056T DE60228056D1 DE 60228056 D1 DE60228056 D1 DE 60228056D1 DE 60228056 T DE60228056 T DE 60228056T DE 60228056 T DE60228056 T DE 60228056T DE 60228056 D1 DE60228056 D1 DE 60228056D1
Authority
DE
Germany
Prior art keywords
pgc
gluconeogenesis
compositions
methods
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60228056T
Other languages
English (en)
Inventor
Bruce Spiegelman
Clifford Hyunsuk Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE60228056D1 publication Critical patent/DE60228056D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60228056T 2001-02-05 2002-02-05 Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1 Expired - Fee Related DE60228056D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26676501P 2001-02-05 2001-02-05
PCT/US2002/003240 WO2002062297A2 (en) 2001-02-05 2002-02-05 Methods and compositions for modulating gluconeogenesis using pgc-1

Publications (1)

Publication Number Publication Date
DE60228056D1 true DE60228056D1 (de) 2008-09-18

Family

ID=23015907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228056T Expired - Fee Related DE60228056D1 (de) 2001-02-05 2002-02-05 Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1

Country Status (8)

Country Link
US (3) US20030045470A1 (de)
EP (1) EP1366059B1 (de)
JP (1) JP2004526436A (de)
AT (1) ATE403665T1 (de)
AU (1) AU2002251873A1 (de)
CA (1) CA2437727A1 (de)
DE (1) DE60228056D1 (de)
WO (1) WO2002062297A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947652B2 (en) 2004-09-03 2011-05-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating PGC-1α to treat huntington's disease
FI20041540A0 (fi) * 2004-11-29 2004-11-29 Markku Laakso Menetelmä diabetesta hoitavien yhdisteiden seulomiseksi
US7763441B2 (en) 2006-03-13 2010-07-27 Wyeth Modulators of gluconeogenesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426411B1 (en) 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
CA2290944C (en) 1997-05-30 2012-03-06 Bruce M. Spiegelman Pgc-1, a novel brown fat ppar.gamma. coactivator

Also Published As

Publication number Publication date
AU2002251873A1 (en) 2002-08-19
EP1366059A2 (de) 2003-12-03
EP1366059A4 (de) 2004-03-31
WO2002062297A3 (en) 2002-10-03
CA2437727A1 (en) 2002-08-15
EP1366059B1 (de) 2008-08-06
US7371529B2 (en) 2008-05-13
WO2002062297A9 (en) 2002-12-12
JP2004526436A (ja) 2004-09-02
US20080248475A1 (en) 2008-10-09
ATE403665T1 (de) 2008-08-15
WO2002062297A2 (en) 2002-08-15
US20050234001A1 (en) 2005-10-20
US20030045470A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
ATE449168T1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
MY146548A (en) Certain chemicals entities, compositions, and methods
DE602006021223D1 (de) Verfahren zur identifizierung von trpv2-modulatoren
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2007094755A3 (en) Compositions and methods for modulating cognitive function
DE602004022020D1 (de) Oligomere verbindungen zur modulation der expression von survivin
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
DE602004020657D1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
NO20065768L (no) Karbonsamid-opioidforbindelser
ATE471722T1 (de) Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE444488T1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation
DE60228056D1 (de) Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1
DE50114193D1 (de) Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren
DE69943374D1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
ATE420176T1 (de) Der eaat2-promotor und dessen verwendung
ATE497015T1 (de) Verfahren zum auswählen von modulatoren der mitochondrialen nad-abhängigen deacetylase, sirt3
IL203968A0 (en) Photodamage modulator for treating uv photodamage

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee